Challenges, controversies, and advancements in breast surgery: Insights from ASBrS 2017
The American Society of Breast Surgeons (ASBrS) Annual meeting is the premier event of the year for surgeons who treat breast disease: hosting thousands of surgeons, medical device companies, thought leaders, and academics seeking the latest advancements and learnings in breast surgery. Leaders gathered together in Las Vegas from April 26 to 30. This year the annual meeting boasted attendance of over 1700 - the highest attended edition yet.
In addition to catching up with existing and prospective MarginProbe...
The American Society of Breast Surgeons Annual Meeting 2017
Collectively improving the standard of breast cancer treatment at ASBrS 2017
About the American Society of Breast Surgeons (ASBS)
In the organization’s own words, “The American Society of Breast Surgeons, the primary leadership organization for general surgeons who treat patients with breast disease, is committed to continually improving the practice of breast surgery by serving as an advocate for surgeons who seek excellence in the care of breast patients. This mission is accomplished by providing a forum for the exchange of...
The Wall Street Journal: If Surgery Got Cancer in One Try
Healthcare Reporter Lucette Lagnado profiles MarginProbe in The Wall Street Journalfeaturing Dr. Freya Schnabel, Dr. Alice Police, Dr. Vincent Reid, Dune Medical CEO Lori Chmura and more.
“Lora Mosca, learned she had breast cancer in November and decided on a lumpectomy to remove an early-stage tumor.
“Ms. Mosca, a 57-year-old retired probation officer, remembers how worried she was after surgery. ‘That is all you think about—did they get it all out?’ she says. She found herself wondering, ‘Should I have had...
Dune Medical’s MarginProbe Surpasses Use In 10,000 Breast Cancer Patients
(January 9, 2017 – Paoli, PA) Dune Medical Devices’ intraoperative margin assessment device MarginProbe has surpassed use in 10,000 breast cancer patients.
MarginProbe is the first commercial product based on Dune Medical’s proprietary radio frequency (RF) spectroscopy technology. Receiving U.S. FDA Premarket Approval in December 2012, it has been helping surgeons ensure clear margins in lumpectomy procedures since 2013. Peer-reviewed studies show MarginProbe reduces re-excision rates in lumpectomy procedures by 50 – 79 percent.
Recent reports show that 21.6% of...
It has been a very busy and exciting year for the Dune Medical Team. It is with enthusiasm that we carry the progress made in 2016 into the New Year, continue to grow, and help physicians know that they “got it all” during lumpectomy surgery. As this year comes to a close, we want to share the successes of the 4th quarter that have paved the way for the fantastic year to come.
10,000 patients receiving the MarginProbe advantage